In the second interview of the series, Paul Sieber, MD, provides expert insights on the management of adverse effects seen in patients receiving leuprolide for the treatment of advanced/metastatic prostate cancer.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.